Cybin Inc., a clinical-stage neuropsychiatry company, will participate in a Water Tower Research Fireside Chat on May 29, 2025. During the event, CEO Doug Drysdale will discuss the evolution of interventional psychiatry clinics, the importance of Cybin's partnership with Osmind, the progress of the CYB003 Phase 3 program, and the impact of strategic clinical partnerships and the Thermo Fisher collaboration. Upcoming milestones and the FDA's stance on psychedelics will also be covered.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.